Roughly 40% of Wegovy prior authorization (PA) requests are denied on first submission — and most denials are reversible if your documentation is right. To get Wegovy covered by commercial insurance in 2026, your chart needs an obesity diagnosis (E66.01) with BMI ≥30, OR BMI ≥27 plus one qualifying comorbidity (hypertension, dyslipidemia, Type 2 diabetes, cardiovascular disease, sleep apnea, or NAFLD), AND documented prior weight-loss attempts (typically 3-6 months of diet/exercise on the chart). Once approved, the Wegovy Savings Card drops your monthly cost to $25. If your PA is denied and you've exhausted the peer-to-peer and formal appeal process, the four legitimate cheaper paths in June 2026 are Medicare Bridge $50/mo (launches July 1), NovoCare cash-pay $249/mo, compounded semaglutide $99/mo via Embody, or TrimRx at $199/mo (Editor's Choice, US-licensed prescribers). Here's the full PA playbook — exact criteria, documentation checklist, the 4 most common denial reasons, the copy-paste appeal letter template, and what to do if your plan refuses outright.
Quick answer: the PA decision tree
| Your situation | What to do | Expected cost | |---|---|---| | BMI ≥30, commercial insurance, no prior PA filed | Submit PA with full documentation | $25/mo with Wegovy Savings Card | | BMI 27-29 + hypertension/dyslipidemia/T2D/sleep apnea | Submit PA with comorbidity ICD-10 + lab proof | $25/mo with Wegovy Savings Card | | PA denied — first submission | Request peer-to-peer review within 7 days | $25/mo if reversed | | PA denied — peer-to-peer failed | File formal appeal with appeal letter template (below) | $25/mo if reversed | | Formal appeal denied | File external/independent review (IRO) | $25/mo if reversed | | All appeals exhausted | Switch to one of 4 cheaper paths | $50-$249/mo | | Medicare Part D + qualifying tier | Medicare GLP-1 Bridge (launches Jul 1) | $50/mo | | Cash-pay, no insurance | NovoCare direct, or compounded | $99-$249/mo |
What "prior authorization" actually means for Wegovy
Prior authorization is a cost-control mechanism. Before your insurer pays for an expensive drug, your prescriber must submit clinical documentation proving you meet the medical necessity criteria. For Wegovy, that bar is high because the list price is $1,349/month and most patients stay on indefinitely.
Who runs the PA process: your prescriber's office submits the request to either your insurance plan directly or to the plan's Pharmacy Benefits Manager (PBM) — usually CVS Caremark, Express Scripts, or OptumRx. The PBM uses an automated algorithm against the chart documentation, then escalates ambiguous cases to a clinical reviewer.
Typical turnaround: 2-5 business days for a clean submission, 7-14 days if additional documentation is requested, 30+ days if appealed.
Approval duration once granted: most plans authorize Wegovy for 6-12 months, with re-authorization requiring proof of ≥5% body weight loss to continue.
The exact criteria insurers use to approve or deny
These are the standard Wegovy PA criteria across the major commercial plans in 2026. Some plans add proprietary requirements (United, Aetna, Cigna each have slight variations), but this covers ~90% of what you'll face:
Primary eligibility (one of these must be true):
1. BMI ≥30 (obesity) — documented from a recent in-office weight and height measurement, not patient-reported. 2. BMI ≥27 AND at least one of these comorbidities documented in the chart: - Hypertension (E11.x or I10) with current BP readings or active antihypertensive therapy - Dyslipidemia (E78.x) with lipid panel showing LDL >130 or triglycerides >150 - Type 2 diabetes (E11.x) with A1C ≥6.5 - Cardiovascular disease (I25.x, I50.x, etc.) with documented event or imaging - Obstructive sleep apnea (G47.33) with sleep study confirmation - Non-alcoholic fatty liver disease / MASH (K76.0, K75.81) with imaging or biopsy
Documented lifestyle modification attempt:
- Most plans require 3-6 months of documented diet/exercise effort before Wegovy approval. This must be in the chart — "patient reports diet attempts" is not enough. Best practice: prescriber documents specific intervention (Mediterranean diet, structured exercise program, dietitian visits, etc.) with dates and outcomes.
No contraindications:
- Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (boxed warning).
- Pancreatitis history (relative contraindication; most plans require physician justification).
- Current pregnancy or active conception attempts (contraindicated).
- Age <18 (Wegovy approved 12+, but pediatric PA criteria differ).
Specific to weight loss indication (not Ozempic):
- The PA must be coded under obesity (E66.01) or BMI with comorbidity (E66.3 or Z68.3x-Z68.4x). Wegovy PAs coded as Type 2 diabetes are routinely denied because Ozempic is preferred for that indication.
What to bring to your prescriber visit
The four documentation gaps that trigger ~80% of first-submission denials, and what to do about each:
1. Recent in-office BMI measurement (not self-reported). Ask for weight and height to be measured at this visit, not pulled from a 2-year-old chart. PA reviewers reject "patient reports BMI 32" — they want a measured value within the last 6-12 months.
2. Lab proof of the comorbidity claim. If you're going for the BMI 27-29 + comorbidity route, bring or request labs: - Hypertension: bring 2-3 recent BP readings (home cuff or pharmacy kiosk readings are fine, dated and documented). - Dyslipidemia: lipid panel within 12 months. - T2D or prediabetes: A1C within 6 months. - Sleep apnea: sleep study report or CPAP prescription. - NAFLD: ultrasound, FibroScan, or biopsy report.
3. Documented lifestyle modification. This is the biggest gap. Bring a clear narrative: - "I tried [specific diet — Mediterranean, Whole30, calorie tracking, Noom, WeightWatchers] from [start date] to [end date]." - "I worked out [N] days per week at [gym/home/program] for [duration]." - "I met with a dietitian on [dates] — name and credentials if available." - Weight tracking app screenshots, gym attendance logs, dietitian notes — anything that lands in the chart.
4. Clean diagnosis coding. Ask your prescriber to confirm the PA will be submitted with E66.01 + a Z68.3x-Z68.4x BMI code + a separate ICD-10 for the comorbidity. Multi-code submissions get approved at meaningfully higher rates than single-code submissions.
What to say (and not say) at your appointment
Say: - "I want to be evaluated for Wegovy for weight loss." - "I've been doing [specific diet] and [specific exercise] for [duration]." - "My weight has [plateaued/regained] despite consistent effort." - "I'm concerned about [comorbidity if relevant] and want to be proactive about my metabolic health."
Don't say: - "I want Ozempic instead." (Ozempic is for T2D; insurance will deny Ozempic for weight loss in non-diabetics.) - "I just want to lose weight for [a wedding / vacation / cosmetic reason]." (Reviewers screen for cosmetic-only intent.) - "I've tried diets but never stuck to one." (Reviewers want documented effort, not abandonment.) - "My friend got it covered, so why won't my plan cover it?" (Each plan's PA is independent.)
The 4 most common denial reasons and how to overturn each
Denial 1: "BMI below threshold." What happened: chart BMI is <30 and no comorbidity was coded, OR chart BMI is <27. Fix: get a measured in-office BMI within 30 days, ensure a comorbidity ICD-10 is on the chart if BMI 27-29, and resubmit.
Denial 2: "No documented lifestyle modification." What happened: chart lacks specific diet/exercise narrative or duration. Fix: prescriber adds chart note documenting your specific dietary intervention, exercise pattern, and dietitian/coaching visits with dates. Resubmit with updated documentation.
Denial 3: "Step therapy required." What happened: plan requires you try a cheaper preferred drug first (often phentermine, contrave, or orlistat). Fix: either try the preferred drug for 3 months and document failure, OR file a step-therapy exception citing intolerance/contraindication. Some plans accept clinical exception for documented food noise, binge eating disorder history, or prior GLP-1 trial with effective response.
Denial 4: "Diagnosis code mismatch." What happened: PA submitted with diagnosis that doesn't support obesity indication (e.g., metabolic syndrome only, or PCOS only). Fix: resubmit with E66.01 + BMI Z-code + the appropriate comorbidity ICD-10. See our Ozempic for PCOS guide for why PCOS alone doesn't qualify.
The peer-to-peer review: how to win it
After a first denial, you have a 7-day window to request a peer-to-peer (P2P) review. This is a phone call between your prescriber and the insurance company's medical director — usually 5-10 minutes. The P2P reverses roughly 40-50% of initial denials when the prescriber is prepared.
What your prescriber needs to know for the P2P: - Your exact BMI, height, weight, age, and date measured. - The comorbidity ICD-10s and supporting labs/notes by date. - The specific lifestyle modification you attempted (diet name, duration, weight outcome). - Any prior pharmacotherapy attempts and outcomes. - The clinical rationale for Wegovy specifically (e.g., "highest-efficacy obesity medication on formulary; semaglutide has cardiovascular outcome data from SELECT trial").
P2P best practice: if your prescriber's office offers "we'll handle the P2P," ask if a nurse or NP is calling, or the actual prescribing physician. Physician-to-physician P2Ps reverse at higher rates than nurse-to-physician. If your prescriber's office isn't comfortable with P2P, ask to be referred to an obesity medicine specialist (look for ABOM-certified physicians) who handles these regularly.
Formal appeal: the copy-paste letter template
If P2P fails, you have 60-180 days (varies by plan) to file a formal written appeal. Use this template — fill in the bracketed sections:
``` [Date]
[Insurance Company Name] Appeals Department [Address from denial letter]
Re: Formal Appeal of Prior Authorization Denial Member: [Your Full Name] Member ID: [from your insurance card] Date of Denial: [from denial letter] Drug Requested: Wegovy (semaglutide 2.4 mg) Denial Reason Cited: [exact reason from denial letter]
Dear Appeals Reviewer,
I am formally appealing the prior authorization denial dated [date] for Wegovy (semaglutide 2.4 mg) prescribed by [prescriber name, NPI, credentials].
Clinical justification: 1. Diagnosis: I have a documented BMI of [X.X] measured in-office on [date] ([record citation if available]), which exceeds the obesity threshold (BMI ≥30) under the plan's medical necessity criteria. [OR: BMI [X.X] with documented [comorbidity] supported by [lab/study from date].] 2. Lifestyle modification: I have documented [N] months of structured lifestyle intervention, including [specific diet] from [date to date] and [specific exercise] [N] times per week, with [outcome: plateau, partial response, or regain]. 3. Clinical rationale: Wegovy is the most efficacious FDA-approved pharmacotherapy for chronic weight management with proven cardiovascular benefit (SELECT trial, NEJM 2023). It is the appropriate next step in my stepwise treatment plan. 4. Plan formulary: Wegovy is on the plan's covered formulary for this indication.
I respectfully request that this denial be overturned and the requested authorization be approved.
Supporting documentation enclosed: - Recent in-office BMI measurement - Lab values supporting comorbidity diagnosis (if applicable) - Prescriber chart notes documenting lifestyle modification history - Prescriber letter of medical necessity
Sincerely, [Your name and signature]
cc: [Prescriber name, address] ```
Submission notes: send by certified mail with return receipt. Most plans also accept fax submission to the appeals department. Keep copies of everything. Most plans must respond within 30 days (urgent appeals within 72 hours).
External / Independent Review (IRO)
If your formal appeal is denied, you have the right to an external review by an Independent Review Organization (IRO) under the Affordable Care Act. This is the most powerful step in the process because:
- The IRO is not affiliated with your insurance company.
- The decision is binding on your insurer.
- Statistics from the National Association of Insurance Commissioners show roughly 40-50% of IRO reviews overturn the insurer's denial for weight-loss medications.
How to file: your denial letter must include IRO contact information. You typically have 4 months from the final internal denial to request external review. Most states have free patient advocacy programs that will file on your behalf — check Patient Advocate Foundation or your state insurance commissioner.
If all appeals are exhausted: the 4 cheaper paths
If your plan refuses coverage after IRO review (or you don't have time to appeal), here are the legitimate fallback paths in June 2026, ranked by total cost over 6 months:
Path 1 — Compounded semaglutide via Embody ($99/month). Same active molecule as Wegovy. US 503A licensed pharmacy, US prescriber consultation. Cheapest legitimate path in the market. 6-month cost: $594. Full provider grid: cheapest compounded semaglutide ranking.
Path 2 — Yucca Health compounded semaglutide ($146/month on 6-month plan). Strong price-to-credentialing balance. 6-month cost: $876.
Path 3 — TrimRx compounded semaglutide ($199/month). Editor's Choice. Flat all-inclusive pricing at any dose. US-licensed clinicians, monthly check-ins. Best if you want clinical supervision while paying cash. 6-month cost: $1,194.
Path 4 — NovoCare direct cash-pay ($249/month). Brand Wegovy direct from Novo Nordisk. No insurance navigation required, no compounded substitution. 6-month cost: $1,494. Useful if you specifically want the FDA-approved brand and your plan refuses.
Bonus path — Medicare GLP-1 Bridge ($50/month from July 1, 2026). If you're on Medicare Part D and meet the tier criteria (BMI ≥35; or ≥30 with HF/uncontrolled HTN/CKD; or ≥27 with prediabetes/prior MI/stroke/PAD), the Bridge program covers Wegovy at $50/month starting July 1. See our Medicare Bridge enrollment guide for the exact qualifications.
For the full breakdown of every legitimate Wegovy path see our How to Get Wegovy Cheaper guide.
State-specific notes
A few state-level wrinkles to know:
- California, New York, New Jersey: state insurance commissioners have unusually patient-friendly external review processes. ~55-60% IRO reversal rate for weight-loss drug appeals.
- Texas, Florida, Georgia: more restrictive PA criteria in some plans (Aetna, Cigna especially). Step therapy with phentermine is more commonly required.
- All states: if you're enrolled in a self-funded employer plan (ERISA), state-level external review may not apply — your plan's internal review may be the final step. Check the plan document.
Regulatory caveat: FDA compounded comment period closes June 29, 2026
If you're considering the compounded fallback path, the FDA's proposed 503B rule (May 1, 2026) closes its comment period on June 29, 2026 (7 days from today). The proposal would permanently exclude semaglutide, tirzepatide, and liraglutide from large-scale 503B compounding. 503A patient-specific compounding (which is what Embody, Yucca, TrimRx, and MyStart use) is unaffected by this proposal and continues regardless of outcome. Full analysis: FDA 503B Explainer.
FAQ
How long does Wegovy prior authorization take? 2-5 business days for clean first submission. 7-14 days if additional documentation requested. 30 days for formal written appeal, 72 hours for urgent appeals, 30-45 days for external IRO review.
Can I appeal a Wegovy denial myself, or does my doctor have to? Both. The patient has independent appeal rights under the Affordable Care Act. In practice, prescriber-driven appeals win at higher rates because they include clinical documentation. The strongest appeals are co-submitted: prescriber letter + patient appeal letter.
Does Medicare cover Wegovy in 2026? Yes — starting July 1, 2026, Medicare Part D covers Wegovy under the GLP-1 Bridge program at $50/month for patients meeting the tier criteria. Before July 1, Medicare did not cover any GLP-1 for weight loss alone. See our Medicare Bridge guide for the exact qualifications.
Will my employer plan cover Wegovy if it's not on the formulary? Usually no. Self-funded ERISA plans set their own formulary. You can request a formulary exception through the same PA process, but exception approval rates are much lower than standard PA approval rates. Talk to your HR benefits team about whether weight-loss drug coverage is being added at the next plan year.
Is compounded semaglutide as effective as Wegovy? The active molecule is identical. Effectiveness depends on dose, adherence, and titration — not on whether the pharmacy is Novo Nordisk or a US 503A compounder. Real-world adherence is often higher on compounded programs because the cost barrier is lower. For deeper detail see our Ozempic-to-compounded switching guide — the same logic applies to Wegovy-to-compounded.
What if my doctor won't help with the appeal? You have two options: 1) find an obesity medicine specialist (look for ABOM-certified) — they handle these PAs frequently and have boilerplate appeal letters ready. 2) Use a free patient advocate service like Patient Advocate Foundation, which will draft and submit appeals on your behalf at no cost. Or 3) skip the brand-and-insurance path entirely and switch to a compounded program like TrimRx or Embody — no PA required.
Should I switch to Zepbound if Wegovy isn't covered? Possibly. Some plans cover Zepbound (tirzepatide) but not Wegovy, and vice versa. Check your plan formulary before starting the PA process. If your plan covers Zepbound, the same PA criteria apply with the Zepbound Savings Card dropping you to $25/month. See our tirzepatide vs semaglutide comparison for the molecule-level differences.
What's the success rate of formal Wegovy appeals? Roughly 40-50% of initial PA denials are overturned via peer-to-peer review when the prescriber is well-prepared. Of remaining denials that go to formal written appeal, another ~30-40% are overturned. Of appeals that proceed to external IRO review, ~40-50% are reversed. End-to-end, a well-documented, fully-appealed Wegovy PA has a ~70-80% chance of approval — but it can take 3-6 months.
For our full provider grid see the cheapest GLP-1 programs page. For the long-term cardiovascular and kidney case for staying on a GLP-1, see our 90,000-patient Ozempic safety analysis. For switching from brand to compounded, see our step-by-step switching guide. For the regulatory backdrop on the compounded fallback path, see our FDA 503B explainer.